New York: Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster ⁠cancer treatment Ibrance, even as the Trump administration pressures them for cuts, according to data provided exclusively by healthcare research firm 3 Axis Advisors . The number of price increases for 2026 is up from the same point last year, when drugmakers unveiled plans for raises on more than 250 drugs. The median of this year's price hikes

SINGAPORE, Jan. 1, 2026 /PRNewswire/ -- Boyang Wang, founder of Singapore-based longevity investment firm Immortal Dragons, has issued a public statement following his participation in a recent episode of the Financial Times' technology podcast series, Tech Tonic, titled "Defying Death: The Longevity Lab." Continue Reading Immortal Dragons Comments on Longevity Regulation and Investment Trends Following FT Podcast Appearance The episode examines Singapore's emergence as a global hub for longevit

DUBLIN--(BUSINESS WIRE)--The "Insomnia: Opportunity Assessment and Forecast Update" report has been added to ResearchAndMarkets.com's offering. This report covers the 7MM and provides an Excel-based forecast model for the Insomnia market through 2032. Z-drugs are the most common first-line treatment for insomnia across the US and 5EU. The insomnia pipeline in the 7MM is sparse but varied, containing products with varying mechanisms of action. There are five pipeline products in Phase II and III

2026 Expected to Be a Record Year AVACEN was founded by two military families. We have always helped our military community whenever possible. Our dream has continuously been to have an AVACEN device available to all Veterans in need.” — Danielle Forsgren, President CARLSBAD, CA, UNITED STATES, December 31, 2025 / EINPresswire.com / -- AVACEN Medical ® (AVACEN), a leading developer, manufacturer, and the #1 global distributor of noninvasive, FDA-Cleared Class II, palm-based, thermo-therapy medic

RIYADH, SAUDI ARABIA, December 31, 2025 / EINPresswire.com / -- King Faisal Specialist Hospital & Research Centre continues to play a leading regional role in pediatric stem cell transplantation through a highly specialized program serving children with malignant and non-malignant diseases, inherited blood disorders, immunodeficiencies, and metabolic conditions. The Pediatric Stem Cell Transplant Program performs approximately 130 transplants annually for patients from birth to under 14 years of

DUBLIN--(BUSINESS WIRE)--The "NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2025 Update" company profile has been added to ResearchAndMarkets.com's offering. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. NovoCure Ltd (NovoCure) is an oncology company with a focus on the development and commercialization of novel delivery systems for t

Avinasi Labs Enables a New Funding & Revenue Model for Clinical Stage Assets via DeLong Protocol SAN FRANCISCO, CA, UNITED STATES, December 31, 2025 / EINPresswire.com / -- Avinasi Labs , an AI-native longevity infrastructure company building the world’s first liquid foundation model for aging science, today announced a $15 million clinical-stage assetization Memorandum of Understanding (“MoU”) with Fermion , a cutting-edge AI-driven biotechnology company advancing small-molecule drug discovery.

IDAHO FALLS, Idaho, Dec. 31, 2025 /PRNewswire/ -- International Isotopes Inc. ("INIS" or the "Company") (OTCQB:INIS) today announced that it has filed a Certificate of Amendment in the State of Texas to change our legal name to Radnostix, Inc. Effective immediately, we will officially begin to rebrand all of our operations under the Radnostix name. INIS was started in 1995 as a company focused on irradiation and manufacturing of industrial radioisotope products. Over the years, our focus has evo

Board brings together internationally recognized leaders in immunology, oncology, and translational science to guide next-gen immune-engineering platforms. FORT LAUDERDALE, FL, UNITED STATES, December 31, 2025 / EINPresswire.com / -- Lurex Bio Inc., a biotechnology company advancing next-generation immune-engineering platforms, today announced the formation of its Scientific Advisory be Board (SAB), composed of internationally recognized leaders in immunology, oncology, translational science, an

New Delhi: While patients in India familiarize themselves with the once-weekly GLP-1 injectable routine, Lupin is betting on a biweekly brand to leapfrog its rivals in country’s booming type-2 diabetes and weight-loss drug markets. Without disclosing the deal financial terms, earlier this week the Mumbai-based drugmaker announced an exclusive distribution agreement with China’s Gan & Lee Pharmaceuticals , in-licensing India rights of an investigational fortnightly GLP-1 receptor agonist , ‘ Bofa